JP2022541550A - 先天性副腎過形成を処置する方法 - Google Patents

先天性副腎過形成を処置する方法 Download PDF

Info

Publication number
JP2022541550A
JP2022541550A JP2022503463A JP2022503463A JP2022541550A JP 2022541550 A JP2022541550 A JP 2022541550A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022541550 A JP2022541550 A JP 2022541550A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
subject
upper limit
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541550A5 (https=
Inventor
ゴーシュ，サンギータ
バーンズ，クリストファー
フアン，マイケル
Original Assignee
スプルース バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スプルース バイオサイエンシーズ，インク． filed Critical スプルース バイオサイエンシーズ，インク．
Publication of JP2022541550A publication Critical patent/JP2022541550A/ja
Publication of JP2022541550A5 publication Critical patent/JP2022541550A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2022503463A 2019-07-19 2020-07-20 先天性副腎過形成を処置する方法 Pending JP2022541550A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876176P 2019-07-19 2019-07-19
US62/876,176 2019-07-19
US202063047822P 2020-07-02 2020-07-02
US63/047,822 2020-07-02
PCT/US2020/042820 WO2021016208A1 (en) 2019-07-19 2020-07-20 Methods of treating congenital adrenal hyperplasia

Publications (2)

Publication Number Publication Date
JP2022541550A true JP2022541550A (ja) 2022-09-26
JP2022541550A5 JP2022541550A5 (https=) 2023-07-28

Family

ID=74193935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503463A Pending JP2022541550A (ja) 2019-07-19 2020-07-20 先天性副腎過形成を処置する方法

Country Status (11)

Country Link
US (2) US20220133742A1 (https=)
EP (1) EP3986416A4 (https=)
JP (1) JP2022541550A (https=)
KR (1) KR20220052927A (https=)
CN (1) CN114423436A (https=)
AU (1) AU2020318970B2 (https=)
BR (1) BR112022000956A2 (https=)
CA (1) CA3147891A1 (https=)
MX (1) MX2022000812A (https=)
TW (1) TW202116324A (https=)
WO (1) WO2021016208A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
KR20240023691A (ko) * 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
MD20210019A2 (ro) 2021-04-12 2022-10-31 Максим МАСЮТИН Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
JP2024539907A (ja) * 2021-11-19 2024-10-31 スプルース バイオサイエンシーズ，インク． チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503030A (ja) * 2014-01-21 2017-01-26 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
WO2019036503A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
WO2019036472A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
CN101516835A (zh) * 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US20150094310A1 (en) * 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
EP4643950A3 (en) * 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) * 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503030A (ja) * 2014-01-21 2017-01-26 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
WO2019036503A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
WO2019036472A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP2020530832A (ja) * 2017-08-14 2020-10-29 スプルース バイオサイエンシズ インコーポレイテッド 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2020530831A (ja) * 2017-08-14 2020-10-29 スプルース バイオサイエンシズ インコーポレイテッド 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Also Published As

Publication number Publication date
US20240261300A1 (en) 2024-08-08
CN114423436A (zh) 2022-04-29
AU2020318970A1 (en) 2022-03-03
EP3986416A4 (en) 2023-06-28
AU2020318970B2 (en) 2026-04-16
TW202116324A (zh) 2021-05-01
US20220133742A1 (en) 2022-05-05
MX2022000812A (es) 2022-02-16
KR20220052927A (ko) 2022-04-28
EP3986416A1 (en) 2022-04-27
WO2021016208A1 (en) 2021-01-28
CA3147891A1 (en) 2021-01-28
BR112022000956A2 (pt) 2022-04-05

Similar Documents

Publication Publication Date Title
US20240261300A1 (en) Methods of treating congenital adrenal hyperplasia
JP7573080B2 (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
AU2021324839B2 (en) Methods and compositions for treating polycystic ovary syndrome
JP7285222B2 (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
HK40092755B (zh) 用於治疗多囊卵巢综合征的方法和组合物
HK40092755A (zh) 用於治疗多囊卵巢综合征的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250324